Actively Recruiting
Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer
Led by Centre Henri Becquerel · Updated on 2026-01-02
48
Participants Needed
1
Research Sites
183 weeks
Total Duration
On this page
Sponsors
C
Centre Henri Becquerel
Lead Sponsor
E
Erasmus Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer
CONDITIONS
Official Title
Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Woman older than 18 years
- Diagnosis of early breast cancer
- CT scan performed within the last 3 months including L3 vertebra level
- Planned treatment with docetaxel at 100 mg/m² as adjuvant chemotherapy
You will not qualify if you...
- HER2 amplified or triple negative tumors
- Pregnant or breastfeeding women
- Patients under guardianship or curatorship
- Receiving another cytotoxic drug or targeted therapy at the same time
- Presence of psychosocial disorders
- Received another cytotoxic drug or targeted therapy within 20 days before blood collection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Henri Becquerel
Rouen, France, 76038
Actively Recruiting
Research Team
F
Florian Clatot, Prof
CONTACT
D
Doriane Richard, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here